ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Iksuda Therapeutics and Femtogenix Sign License Agreement pharmafocusasia
March 07, 2019Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.
Pharma Sources Insight January 2025
